On Friday, May 17, 2019, the Centers for Medicare and Medicaid Services issued Medicaid Drug Rebate Program (MDRP) manufacturer release #110. The release includes information for manufacturers regarding treatment of rebates paid to Medicare Advantage Prescription Drug (MA-PD) plans for Part B drugs when calculating MDRP pricing metrics, such as Average Manufacturers Price (AMP) and Best Price, as well as Average Sales Price (ASP); further instructions for manufacturers that wish to terminate their National Drug Rebate Agreement (NDRA) to assure prompt receipt by CMS of the termination notice; and further information regarding new manufacturer requests for an NDRA with respect to optional and mandatory effective dates for state coverage of new covered outpatient drugs.
No hay comentarios:
Publicar un comentario